Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Treatment of frequent heartburn (FDA-approved for over-the-counter use),Gastroesophageal reflux disease (GERD),Erosive esophagitis,Duodenal ulcer,Gastric ulcer,Zollinger-Ellison syndrome,Helicobacter pylori eradication (as part of combination therapy)
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Magnesium hydroxide: not applicable (local action); omeprazole: 0.5-1 hour (terminal); sodium bicarbonate: not applicable (buffering agent). Omeprazole's half-life is short but pharmacodynamic effect (acid suppression) lasts ~24 hours due to covalent binding to proton pumps.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Omeprazole is extensively metabolized in the liver via CYP2C19 and CYP3A4; its metabolites are inactive. Magnesium hydroxide and sodium bicarbonate are not metabolized; they act locally and are partially absorbed. Sodium bicarbonate is converted to carbon dioxide and water via carbonic anhydrase.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Magnesium hydroxide: primarily fecal (unabsorbed magnesium), renal (absorbed magnesium); omeprazole: renal (~77% as metabolites) and fecal (~23%); sodium bicarbonate: renal (as bicarbonate or CO2).
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Magnesium hydroxide: negligible; omeprazole: 95% (albumin and alpha1-acid glycoprotein); sodium bicarbonate: negligible.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Magnesium hydroxide: not applicable (local); omeprazole: 0.3-0.5 L/kg (extensive tissue distribution); sodium bicarbonate: 0.5-1 L/kg (total body water).
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Magnesium hydroxide: not absorbed orally; omeprazole: 30-40% (oral, delayed-release formulation); sodium bicarbonate: 100% (oral, completely absorbed).
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of magnesium accumulation and sodium overload. For e GFR 30-59 m L/min/1.73m², reduce dose to one tablet every other day and monitor serum magnesium and sodium.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce omeprazole dose to 10 mg (not available in this combination) or consider alternative; use with caution. Child-Pugh C: Contraindicated due to omeprazole accumulation.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Not recommended for use in pediatric patients (safety and efficacy not established).
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Use with caution due to increased risk of electrolyte imbalance (hypermagnesemia, metabolic alkalosis) and renal impairment. Consider reducing dose to one tablet every other day. Monitor renal function and serum electrolytes.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
None
None
Long-term use (≥1 year) may increase risk of osteoporosis-related fractures; hypomagnesemia with prolonged PPI use; cyanocobalamin (vitamin B12) deficiency with long-term acid suppression; magnesium hydroxide may cause diarrhea; sodium bicarbonate may cause metabolic alkalosis, fluid retention, and worsen hypertension or heart failure; acute interstitial nephritis reported with PPIs; monitor renal function; interaction with clopidogrel (omeprazole reduces clopidogrel's active metabolite); increased risk of Clostridium difficile infection; avoid concurrent use of atazanavir or nelfinavir.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Hypersensitivity to any component; Concurrent use of rilpivirine-containing products; Severe renal impairment (Cr Cl <30 m L/min) due to risk of magnesium toxicity; Sodium-restricted diet (due to sodium content); Patients with metabolic alkalosis; Children under 12 years for over-the-counter use (varies by product).
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Take on empty stomach; food reduces omeprazole absorption. Avoid high-fat meals. No known specific food interactions with antacid components.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is considered low risk; magnesium hydroxide can cause hypotonia and respiratory depression in neonates with prolonged use; sodium bicarbonate may lead to fluid overload or alkalosis.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Omeprazole is excreted in breast milk in low amounts (M/P ratio ~0.5); magnesium hydroxide and sodium bicarbonate are poorly absorbed; considered compatible with breastfeeding, but monitor infant for diarrhea or electrolyte imbalance.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No dose adjustment typically required; monitor for magnesium toxicity in renal impairment; consider reduced omeprazole dose if CYP2C19 polymorphisms present; sodium bicarbonate dose should be adjusted to avoid metabolic alkalosis.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
This combination uses sodium bicarbonate to rapidly raise gastric p H, enabling omeprazole absorption (enteric-coated omeprazole may be prematurely released; use non-enteric formulations). Magnesium hydroxide provides additional acid neutralization and a laxative effect. Avoid in patients with renal impairment (risk of magnesium toxicity, sodium overload). Administer on an empty stomach at least 1 hour before meals. Do not split or crush tablets.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Take this medication on an empty stomach at least 1 hour before a meal.,Swallow the tablet whole; do not crush or chew it.,Do not take with other antacids or calcium supplements.,Notify your doctor if you have kidney disease or are on a low-sodium diet.,Common side effects include diarrhea or stomach pain; report severe or persistent symptoms.,Avoid alcohol and NSAIDs as they can worsen stomach irritation.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs COLYTE, answered by our medical review team.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is: One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is . COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.